Weinberg Uri 4

What Happened Uri Weinberg, NovoCure's Chief Medical & Innovation Officer, had 12,992 performance-based restricted stock units vest on 2026-02-28 and sold a total of 10,733 shares in two open-market transactions around that vesting. On 2026-02-27 he sold 7,461 shares at a weighted-average price of $13.84 for proceeds of $103,257 (sell-to-cover to satisfy tax withholding). On 2026-03-02 he sold 3,272 shares at a weighted-average price of $13.33 for proceeds of $43,607. The Form 4 shows the award/vesting as an acquisition (12,992 shares) reported at $0.00 (RSU vesting).

Key Details

• Transaction dates and prices:
  • 2026-02-27: Sale of 7,461 shares @ $13.84 (weighted avg; trades ranged $13.79–$13.91) — $103,257 (F2).
  • 2026-02-28: Acquisition (vesting) of 12,992 performance RSUs @ $0.00 (F3).
  • 2026-03-02: Sale of 3,272 shares @ $13.33 (weighted avg; trades ranged $13.31–$13.36) — $43,607 (F4).
• Total sold: 10,733 shares for ~$146,864; total acquired via vesting: 12,992 RSUs.
• Footnotes:
  • F1: The 7,461-share sale was mandated to cover tax withholding tied to the RSU vesting (a required "sell-to-cover"), not a discretionary trade.
  • F2/F4: Reported sale prices are weighted averages from multiple trades.
  • F3: The 12,992 shares represent vesting of performance-based restricted stock units.
• Shares owned after the transactions: not specified in the provided excerpt.
• Filing: Form 4 filed 2026-03-03; no indication in the filing excerpt that the report was late.

Context

• Vesting of RSUs is compensation-related (an acquisition on Form 4) and the sell-to-cover is a common, issuer-mandated way to satisfy tax withholding; such mandated sales do not necessarily indicate a selling decision by the insider. The separate 3/2 sale appears to be an open-market disposal reported on the Form 4.